Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa

Ndayisaba, Gilles; Yeka, Adoke; Asante, Kwaku Poku; Grobusch, Martin P.; Karita, Etienne; Mugerwa, Henry; Asiimwe, Stephen; Oduro, Abraham; Fofana, Bakary; Doumbia, Seydou; Jain, Jay Prakash; Barsainya, Sarita; Kullak-Ublick, Gerd A.; Su, Guoqin; Schmitt, Esther K.; Csermak, Katalin; Gandhi, Preetam; Hughes, David

Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa

Autor(en):

Ndayisaba, Gilles; Yeka, Adoke; Asante, Kwaku Poku; Grobusch, Martin P.; Karita, Etienne; Mugerwa, Henry; Asiimwe, Stephen; Oduro, Abraham; Fofana, Bakary; Doumbia, Seydou; Jain, Jay Prakash; Barsainya, Sarita; Kullak-Ublick, Gerd A.; Su, Guoqin; Schmitt, Esther K.; Csermak, Katalin; Gandhi, Preetam; Hughes, David

Tübinger Autor(en):

Grobusch, Martin

Erschienen in:

Malaria Journal (2021), Bd. 20, H. 1

Verlagsangabe:

London

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1186/s12936-021-04009-1

ISSN:

1475-2875